Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
The Inner Mongolia Institute of Chinese and Mongolian medicine, Hohhot, China.
Clin Exp Hypertens. 2023 Dec 31;45(1):2195135. doi: 10.1080/10641963.2023.2195135.
Hypertension is one of the most important risk factors for cardio-cerebral vascular diseases, which brings a heavy economic burden to society and becomes a major public health problem. At present, the pathogenesis of hypertension is unclear. Increasing evidence has proven that the pathogenesis of hypertension is closely related to the dysbiosis of gut microbiota. We briefly reviewed relevant literature on gut microbiota and hypertension to summarize the relationship between gut microbiota and hypertension, linked the antihypertension effects of drugs with their modulation on gut microbiota, and discussed the potential mechanisms of various gut microbes and their active metabolites to alleviate hypertension, thus providing new research ideas for the development of antihypertension drugs.
The relevant literature was collected systematically from scientific database, including Elsevier, PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), Baidu Scholar, as well as other literature sources, such as classic books of herbal medicine.
Hypertension can lead to gut microbiota imbalance and gut barrier dysfunction, including increased harmful bacteria and hydrogen sulfide and lipopolysaccharide, decreased beneficial bacteria and short-chain fatty acids, decreased intestinal tight junction proteins and increased intestinal permeability. Gut microbiota imbalance is closely related to the occurrence and development of hypertension. At present, the main methods to regulate the gut microbiota include fecal microbiota transplantation, supplementation of probiotics, antibiotics, diet and exercise, antihypertensive drugs, and natural medicines.
Gut microbiota is closely related to hypertension. Investigating the correlation between gut microbiota and hypertension may help to reveal the pathogenesis of hypertension from the perspective of gut microbiota, which is of great significance for the prevention and treatment of hypertension.
高血压是心脑血管疾病最重要的危险因素之一，给社会带来沉重的经济负担，成为重大的公共卫生问题。目前，高血压的发病机制尚不清楚。越来越多的证据证明，高血压的发病机制与肠道菌群失调密切相关。我们简要综述了肠道菌群与高血压的相关文献，总结了肠道菌群与高血压的关系，将药物的降压作用与其对肠道菌群的调节联系起来，并探讨了各种肠道微生物及其活性代谢物缓解高血压的潜在机制，从而为开发降压药物提供新的研究思路。
系统地从科学数据库（包括爱思唯尔、PubMed、Web of Science、中国知网、百度学术等）和其他文献来源（如草药经典著作）中收集相关文献。
高血压可导致肠道菌群失衡和肠道屏障功能障碍，包括有害菌和硫化氢、脂多糖增加，有益菌和短链脂肪酸减少，肠道紧密连接蛋白减少，肠道通透性增加。肠道菌群失衡与高血压的发生发展密切相关。目前，调节肠道菌群的主要方法包括粪便微生物移植、益生菌、抗生素、饮食和运动、降压药和天然药物的补充。
肠道菌群与高血压密切相关。研究肠道菌群与高血压的相关性，可能有助于从肠道菌群的角度揭示高血压的发病机制，对高血压的防治具有重要意义。
